Q2 2026 saw continued advancement of lead vaccine and immuno-oncology programs, with a narrowed focus following the discontinuation of COVID-19 vaccine development. Net loss narrowed year-over-year, and cash position remained stable as the company prepares for a pivotal clinical trial.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.